Menten AI
Palo Alto
About Menten AI
Menten AI designs new protein drugs and enzymes using quantum computers and machine learning. Proteins are large molecules that can twist into many shapes. Discovering the right shape for a protein to be a drug or a biocatalyst among almost endless possibilities is a major challenge. Menten AI solves this problem by using machine learning and quantum computing to find better starting points for discovery and further development. Quantum computing makes it possible to represent multiple states of the protein simultaneously and efficiently find the best designs. The team created the world’s first peptide designed on a quantum computer and is now working on peptide therapeutics for oncology and neurodegeneration, as well as on enzymes for industrial applications.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $4.0M
- Funding stage: Seed
- Last round: Seed (May 2023)
- Website: menten.ai
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Chemical, Health Care, Life Science
Social Profiles
Canonical: https://fsome.com/organization/menten-ai-40359 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.